Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Study to Evaluate the Efficacy and Safety of GH509 Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)/Non-alcoholic Fatty Liver Disease (NAFLD)

NCT05784779 is registered in ClinicalTrials.gov with 1Globe Biomedical Co., Ltd. as lead sponsor.

NCT NCT05784779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05784779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Study to Evaluate the Efficacy and Safety of GH509 Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)/Non-alcoholic Fatty Liver Disease (NAFLD)
Lead sponsor
1Globe Biomedical Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
February 28, 2023
Completion date
June 28, 2024
Enrollment
180 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nafld, nash